The Latest Cardiac and Vascular News
RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application (BLA) for sotatercept, Merck’s novel investigational activin signaling inhibitor, for the treatment of adult patients […]
SUNNYVALE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) — Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors. Proceeds from the financing will support the clinical advancement of Corsair’s lead product candidate, […]
Exploratory post-hoc analysis of STELLAR shows potential of sotatercept to improve cardiovascular function Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date; safety profile of sotatercept consistent with previous studies and efficacy improvements maintained after one year of therapy Nine Merck-sponsored abstracts […]
This is the first and only single tablet combination therapy to be submitted for review in Europe for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, Belgium, June 26, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of […]
This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all guidelines-recommended treatment pathways RARITAN, N.J., May 30, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson […]
SHANGHAI, Feb. 27, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced positive one-year results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study at the industry’s most leading American Cardiovascular Research Technologies conference (CRT 2023). PADN is an innovative radiofrequency ablation technique in treating PH, was recognized as a CFDA […]
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial hypertension (PAH) PH-ILD shares clinical and pathophysiological features with PAH, however, there is only one currently approved therapy in PH-ILD and unmet need remains high […]
AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use for patients. PAH is a rare and progressive disease with no cure; pulmonary vascular remodeling is believed to drive disease progression and poor outcomes, however, […]
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today […]
– Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 – – Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib – – Statistically Significant Improvements Observed in NT-proBNP and ECHO Measures of Cardiac Structure and Function – – Consistently Positive Results Seen Across Pre-Specified Sub-Groups, Including […]
